AAPG
AAPGHealthcareNASDAQBiotechnology · Last scanned Sep 9, 2026
Scan Results
Daily timeframeAAPG operates in the Biotechnology space. Ascentage Pharma Group International, a clinical-stage biotechnology company, develops therapies for cancers, chronic hepatitis B virus (HBV), and age-related diseases in Mainland China. At a $1.63B market cap, AAPG ranks as a small-cap company within healthcare. The company's primary product candidate is HQP1351, a BCR-ABL inhibitor targeting BCR-ABL1 mutants, including those with the T315I mutation.
Market Cap
$1.63B
Beta
0.67
P/E (TTM)
—
P/E (Fwd)
-16.82
EPS (TTM)
$-2.35
EPS (Fwd)
$-1.04
ROE
-236.6%
ROA
-28.0%
Cash
$1.90B
Total Debt
$2.09B
Free CF
-$956.5M
52W Change
-54.5%
Annual Financials
Cash vs Debt
Where AAPG stands vs its 150-day and 200-day moving averages
As of the September 3, 2026 close, AAPG finished 20.07% below its 150-day moving average ($21.03) and 26.94% below its 200-day moving average ($23.01). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is AAPG overbought or oversold?
At the September 3, 2026 close, AAPG's RSI(14) was 35.2, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The company holds $1.90B in cash, though total debt stands at $2.09B. This level of leverage is common in the industry but worth monitoring as interest rate conditions evolve. Free cash flow is running at -$956.5M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Return on equity stands at -236.6%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has grown from $209.7M (2022) to $574.1M (2025), reflecting a 174% increase over the period.
With a beta below 0.7, AAPG typically sees smaller price swings than the overall market, offering a degree of stability during turbulent periods. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. No single metric tells the full story. Reviewing AAPG's risk profile alongside its fundamentals and technical indicators provides a more complete picture.